{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:26:18Z","timestamp":1787153178911,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gassur.2026.102497","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:25:34Z","timestamp":1784075134000},"page":"102497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-8446","authenticated-orcid":false,"given":"Elio R.","family":"Bitar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Besir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaelyn C.","family":"Cummins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Sears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"El Moheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellyn","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J.","family":"van der Windt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gassur.2026.102497_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.gassur.2026.102497_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.metabol.2018.11.001","article-title":"Obesity and cancer risk: emerging biological mechanisms and perspectives","volume":"92","author":"Avgerinos","year":"2019","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.gassur.2026.102497_bib3","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1007\/s10620-019-05603-9","article-title":"Obesity and the risk of gastrointestinal cancers","volume":"64","author":"Karczewski","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"10481","key":"10.1016\/j.gassur.2026.102497_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.gassur.2026.102497_bib5","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.gassur.2026.102497_bib6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1001\/jama.2022.9009","article-title":"Association of bariatric surgery with cancer risk and mortality in adults with obesity","volume":"327","author":"Aminian","year":"2022","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.gassur.2026.102497_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.gassur.2026.102497_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.gassur.2026.102497_bib9","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0257","article-title":"Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?","volume":"12","author":"Lisco","year":"2023","journal-title":"Endocr Connect"},{"issue":"8","key":"10.1016\/j.gassur.2026.102497_bib10","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.37765\/ajmc.2025.89778","article-title":"Trends in glucagon-like peptide 1 receptor agonist prescribing patterns","volume":"31","author":"Ukhanova","year":"2025","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1016\/j.gassur.2026.102497_bib11","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/jnci\/djaf212","article-title":"GLP-1 receptor agonists: an emerging tool for obesity-related cancer prevention?","volume":"117","author":"Yarmolinsky","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.gassur.2026.102497_bib12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gassur.2026.102497_bib13","series-title":"FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes [Internet]","author":"U.S. Food and Drug Administration","year":"2026"},{"key":"10.1016\/j.gassur.2026.102497_bib14","unstructured":"Centers for Disease Control and Prevention. Adult BMI categories [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2025. Available from: \u3008https:\/\/www.cdc.gov\/bmi\/adult-calculator\/bmi-categories.html\u3009 [Accessed 11 May 2025]."},{"key":"10.1016\/j.gassur.2026.102497_bib15","unstructured":"Ozempic. Ozempic\u00ae dosing [Internet]. Plainsboro (NJ): Novo Nordisk Inc; 2025 Available from: \u3008https:\/\/www.ozempic.com\/how-to-take\/ozempic-dosing.html\u3009[Accessed 11 Jan 2025]."},{"key":"10.1016\/j.gassur.2026.102497_bib16","series-title":"Dosing schedule [Internet]","author":"Wegovy","year":"2025"},{"key":"10.1016\/j.gassur.2026.102497_bib17","series-title":"OZEMPIC prescribing information [Internet]","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.gassur.2026.102497_bib18","series-title":"WEGOVY prescribing information [Internet]","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"10.1016\/j.gassur.2026.102497_bib19","series-title":"Starting and continuing Zepbound [Internet]","author":"Zepbound","year":"2025"},{"key":"10.1016\/j.gassur.2026.102497_bib20","series-title":"ZEPBOUND prescribing information [Internet]","author":"U.S. Food and Drug Administration","year":"2025"},{"issue":"2","key":"10.1016\/j.gassur.2026.102497_bib21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","article-title":"Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes","volume":"29","author":"Abrahami","year":"2018","journal-title":"Epidemiology"},{"key":"10.1016\/j.gassur.2026.102497_bib22","doi-asserted-by":"crossref","first-page":"i581","DOI":"10.1136\/bmj.i581","article-title":"Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study","volume":"352","author":"Azoulay","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.gassur.2026.102497_bib23","first-page":"i5340","article-title":"Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink","volume":"355","author":"Hicks","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.gassur.2026.102497_bib24","article-title":"Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial","volume":"55","author":"Gamborg","year":"2025","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.gassur.2026.102497_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12876-025-04211-4","article-title":"Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","volume":"25","author":"Zhong","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gassur.2026.102497_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078225","article-title":"Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study","volume":"385","author":"Pasternak","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.gassur.2026.102497_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/thy.2024.0387","article-title":"Glucagon-like peptide 1 receptor agonists and risk of thyroid cancer: an international multisite cohort study","volume":"35","author":"Baxter","year":"2025","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.gassur.2026.102497_bib28","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jnci\/djaf163","article-title":"Association between glucagon-like peptidase 1 receptor agonist and obesity-related cancer in overweight or obese patients with type 2 diabetes: a nationwide cohort study","volume":"117","author":"Mao","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.gassur.2026.102497_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103213","article-title":"Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study","volume":"83","author":"Wolff Sagy","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.gassur.2026.102497_bib30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semcancer.2025.07.007","article-title":"Obesity-driven inflammation and cancer risk: a comprehensive review","volume":"114","author":"Lamabadusuriya","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.gassur.2026.102497_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.152822","article-title":"GLP-1 receptor agonists and inflammatory pathway modulation: dual targeting of metabolic and immune dysfunction in insulin resistance","volume":"789","author":"Ngabea","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.gassur.2026.102497_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/onco5040047","article-title":"The role of metabolic inflammation and insulin resistance in obesity-associated carcinogenesis\u2013a narrative review","volume":"5","author":"da Cunha Junior","year":"2025","journal-title":"Onco"},{"issue":"3","key":"10.1016\/j.gassur.2026.102497_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00432-025-06154-5","article-title":"Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway","volume":"151","author":"Wang","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.gassur.2026.102497_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.gassur.2026.102497_bib35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/genes16111352","article-title":"GLP-1 receptor agonists in solid tumour therapy: exploring their anticancer potential and underlying molecular pathways","volume":"16","author":"Lucente","year":"2025","journal-title":"Genes"},{"issue":"21","key":"10.1016\/j.gassur.2026.102497_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194743","article-title":"GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research","volume":"135","author":"Valencia-Rinc\u00f3n","year":"2025","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.gassur.2026.102497_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02032-23","article-title":"Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases","volume":"15","author":"Zeng","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.gassur.2026.102497_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semcancer.2025.09.002","article-title":"Bile acids in liver and gastrointestinal cancer","volume":"116","author":"Monte","year":"2025","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.gassur.2026.102497_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2018.11.017","article-title":"Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery","volume":"156","author":"Albaugh","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26001782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X26001782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:48:16Z","timestamp":1787150896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X26001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1091255X26001782"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102497","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2026.102497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Surgery of the Alimentary Tract. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102497"}}